DDInter458 DDInter1598
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists that possessed oral bioavailability until the approval of [atogepant] in 2021. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.[A189330,A189207]
Cyclosporine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Rimegepant
Cyclosporine {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is downregulated by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine {u} (Compound) causes {v} (Side Effect) Cyst
Cyst {u} (Side Effect) is caused by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Rimegepant
Cyclosporine {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Rimegepant
Cyclosporine {u} (Compound) causes {v} (Side Effect) Cyst
Cyst {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Rimegepant
Cyclosporine {u} (Compound) downregulates {v} (Gene) PROS1
PROS1 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rimegepant
Cyclosporine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Rimegepant
Cyclosporine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cyclosporine (Compound) upregulates CTSD (Gene) and CTSD (Gene) is downregulated by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cyclosporine (Compound) upregulates CTSD (Gene) and CTSD (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cyclosporine (Compound) causes Cyst (Side Effect) and Cyst (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cyclosporine (Compound) upregulates CTSD (Gene) and CTSD (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Rimegepant
Cyclosporine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Rimegepant
Cyclosporine (Compound) causes Cyst (Side Effect) and Cyst (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Rimegepant
Cyclosporine (Compound) downregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant